

## Special Issue

# Recent Advances in Pancreatic Surgery for Pancreatic Ductal Adenocarcinoma

### Message from the Guest Editor

With recent advances in neoadjuvant and adjuvant treatment modalities for pancreatic ductal carcinoma (PDAC), the outcomes of pancreatic surgery have improved. Additionally, there has been notable progress in surgical techniques after neoadjuvant therapy, such as the aggressive combined resection of major vessels, arterial divestment and the introduction of laparoscopic or robotic surgery. The focus of this Special Issue is to consider the following research aspects of PDAC (original or review article): (a) resectability classification, (b) PDAC management according to the resectability classification, (c) the indication of conversion surgery and its outcome, (d) novel surgical techniques used for the combined resection of portal veins and major arteries, and (e) the indication of laparoscopic and robotic surgeries.

---

### Guest Editor

Dr. Shuji Isaji

1. Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Mie University, Tsu 514-0102, Mie, Japan
2. Matsusaka City Hospital, Matsusaka-shi 515-8544, Mie, Japan

---

### Deadline for manuscript submissions

closed (28 February 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/181389](https://mdpi.com/si/181389)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)